{"id":123818,"date":"2024-05-08T13:41:50","date_gmt":"2024-05-08T08:11:50","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=123818"},"modified":"2024-05-08T14:07:30","modified_gmt":"2024-05-08T08:37:30","slug":"pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/","title":{"rendered":"Pharma stock falls 10% despite company reports 30% YoY growth in net profit"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-84898059\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>The shares of the pharmaceutical formulations manufacturer fell up to 10 percent despite the company\u2019s net profit and revenue increased by 48 percent and 30 percent YoY, respectively in the fourth quarter.&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-2325947369\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>With a market capitalization of Rs 432.79 crore, the shares of <strong>Fredun Pharmaceuticals Ltd<\/strong> were trading at Rs 923.95 per share, increasing around 8 percent as compared to the previous closing price of Rs 1,002.35 apiece.\u00a0<\/p><p>Looking into the company&#8217;s performance, Fredun Pharmaceuticals Ltd&#8217;s revenue increased by 35 percent on a quarter-on-quarter basis from Rs. 87.00 crore in Q3FY24 to Rs. 118.03 crore in Q4FY24. Further, revenue increased by 48 percent year on year, from Rs. 79.81 crore in Q4FY23 to Rs. 118.03 crore in Q4FY24.\u00a0<\/p><p>Fredun Pharmaceuticals Ltd&#8217;s net profit increased by 20 percent on a quarter-on-quarter basis, from Rs. 4.22 crore in Q3FY24 to Rs. 5.06 crore in Q4FY24. Further, net profit increased by 30 percent year on year from Rs. 3.89 crore in Q4FY23 to Rs. 5.06 crore in Q4FY24.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-160123330\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>The company&#8217;s profitability measures show an incline in return on equity (RoE) from 9.30 percent in FY 21-22 to 11.21 percent in FY 22-23, while, during the same period return on capital employed (RoCE) increased from 11.71 percent to 17.72 percent. In contrast, the net profit margin (NPM) was 3.93 percent in fiscal year 22-23.&nbsp;<\/p><p>In the company\u2019s recent shareholding pattern, promoters own 48.92 percent while Retail shareholders own a 49.49 percent stake in the company, and domestic Institutional Investors own a 1.59 percent stake.&nbsp;<\/p><p>Fredun Pharmaceuticals Ltd. is an Indian pharmaceutical firm. The company&#8217;s primary business is medicines and healthcare. The company is divided into four business segments: generics (Exports and Fredun Gx), pet healthcare (Freossi), nutraceuticals (Fredun Nutrition), and cosmetics (Bird and Beauty or BnB).&nbsp;<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by:- Abhishek Singh&nbsp;<\/strong><\/p><\/blockquote><h4 class=\"wp-block-heading\" id=\"h-disclaimer\"><strong>Disclaimer<\/strong><\/h4><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-3869637032\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>The shares of the pharmaceutical formulations manufacturer fell up to 10 percent despite the company\u2019s net profit and revenue increased by 48 percent and 30 percent YoY, respectively in the fourth quarter.&nbsp; With a market capitalization of Rs 432.79 crore, the shares of Fredun Pharmaceuticals Ltd were trading at Rs 923.95 per share, increasing around [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":98971,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,13525],"tags":[],"class_list":["post-123818","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-stock-updates"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock falls 10% despite company reports 30% YoY growth in net profit - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"The shares of the pharmaceutical formulations manufacturer fell up to 10 percent despite the company\u2019s net profit and revenue increased by 48 percent and 30 percent YoY, respectively in the fourth quarter.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock falls 10% despite company reports 30% YoY growth in net profit\" \/>\n<meta property=\"og:description\" content=\"The shares of the pharmaceutical formulations manufacturer fell up to 10 percent despite the company\u2019s net profit and revenue increased by 48 percent and 30 percent YoY, respectively in the fourth quarter.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-08T08:11:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-08T08:37:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/\",\"name\":\"Pharma stock falls 10% despite company reports 30% YoY growth in net profit - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"datePublished\":\"2024-05-08T08:11:50+00:00\",\"dateModified\":\"2024-05-08T08:37:30+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"The shares of the pharmaceutical formulations manufacturer fell up to 10 percent despite the company\u2019s net profit and revenue increased by 48 percent and 30 percent YoY, respectively in the fourth quarter.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock falls 10% despite company reports 30% YoY growth in net profit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock falls 10% despite company reports 30% YoY growth in net profit - Trade Brains Features","description":"The shares of the pharmaceutical formulations manufacturer fell up to 10 percent despite the company\u2019s net profit and revenue increased by 48 percent and 30 percent YoY, respectively in the fourth quarter.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock falls 10% despite company reports 30% YoY growth in net profit","og_description":"The shares of the pharmaceutical formulations manufacturer fell up to 10 percent despite the company\u2019s net profit and revenue increased by 48 percent and 30 percent YoY, respectively in the fourth quarter.\u00a0","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2024-05-08T08:11:50+00:00","article_modified_time":"2024-05-08T08:37:30+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/","name":"Pharma stock falls 10% despite company reports 30% YoY growth in net profit - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","datePublished":"2024-05-08T08:11:50+00:00","dateModified":"2024-05-08T08:37:30+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"The shares of the pharmaceutical formulations manufacturer fell up to 10 percent despite the company\u2019s net profit and revenue increased by 48 percent and 30 percent YoY, respectively in the fourth quarter.\u00a0","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-falls-10-despite-company-reports-48-yoy-growth-in-net-profit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock falls 10% despite company reports 30% YoY growth in net profit"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/123818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=123818"}],"version-history":[{"count":2,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/123818\/revisions"}],"predecessor-version":[{"id":123820,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/123818\/revisions\/123820"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/98971"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=123818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=123818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=123818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}